Scholarlink

Background <p>The impact of GLP‑1 receptor agonist exposure prior to pregnancy on pregnancy-related outcomes remains unclear, with studies reporting mixed findings.</p> Methods <p>We conducted a retrospective study evaluating bodyweight and pregnancy-related outcomes among women of reproductive age who were initiated on liraglutide for obesity management and had 2–5 years of follow-up. We compared pregnancies occurring before and after liraglutide exposure in the same women.</p> Results <p>A total of 556 women met the inclusion criteria of which 97 (17.4%) conceived and 459 (82.6%) did not conceive after liraglutide exposure. Baseline characteristics were comparable. After 2–5 years, the mean final weight change was significantly different between women who conceived compared to those who did not (+1.1 ± 11.3% vs. −6.7 ± 9.9%, <i>p</i> &lt; 0.001). The nadir weight reduction on liraglutide in women who conceived was –6.2 ± 7.8%. Gestational weight change was similar in pre- and post-exposure pregnancies (8.0 ± 10.9% vs. 9.2 ± 11.8%, <i>p</i> = 0.554). Additionally, there were no differences in gestational diabetes (32.1% vs. 37.7%, <i>p</i> = 0.629), hypertensive disorders of pregnancy (9.2% vs. 0%, <i>p</i> = 0.063), need for c-section (33.3% vs. 38.9%, <i>p</i> = 0.549), pre-term delivery (3.7% vs. 1.9%, <i>p</i> = 0.500), large for gestational age (5.5% vs. 5.5%, <i>p</i> = 1) or small for gestational age infants (11.1% vs. 9.3%, <i>p</i> = 1) in pre- vs. post-exposure pregnancies. Subgroup analysis demonstrated a lower gestational weight gain with metformin use during pregnancy but was not statistically significant (5.8 ± 9.1 kg vs. 8.2 ± 9.5 kg, <i>p</i> = 0.369). The proportion of women with inconsistent obesity medication use during the study period was higher in those who conceived compared to those who did not (100% vs. 36.5%).</p> Conclusion <p>Preconception liraglutide exposure, followed by discontinuation before pregnancy, was associated with weight regain but not with excess gestational weight gain in our within-individual design. Despite a small sample size, we did not observe increased adverse gestational outcomes in the post-exposure pregnancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Tariq Chukir,
  • Hubaib Haider,
  • Shaunak Sarkar,
  • Siddhant Nair,
  • Rami Kokash,
  • Odette Chagoury,
  • Shahrad Taheri

摘要

Background

The impact of GLP‑1 receptor agonist exposure prior to pregnancy on pregnancy-related outcomes remains unclear, with studies reporting mixed findings.

Methods

We conducted a retrospective study evaluating bodyweight and pregnancy-related outcomes among women of reproductive age who were initiated on liraglutide for obesity management and had 2–5 years of follow-up. We compared pregnancies occurring before and after liraglutide exposure in the same women.

Results

A total of 556 women met the inclusion criteria of which 97 (17.4%) conceived and 459 (82.6%) did not conceive after liraglutide exposure. Baseline characteristics were comparable. After 2–5 years, the mean final weight change was significantly different between women who conceived compared to those who did not (+1.1 ± 11.3% vs. −6.7 ± 9.9%, p < 0.001). The nadir weight reduction on liraglutide in women who conceived was –6.2 ± 7.8%. Gestational weight change was similar in pre- and post-exposure pregnancies (8.0 ± 10.9% vs. 9.2 ± 11.8%, p = 0.554). Additionally, there were no differences in gestational diabetes (32.1% vs. 37.7%, p = 0.629), hypertensive disorders of pregnancy (9.2% vs. 0%, p = 0.063), need for c-section (33.3% vs. 38.9%, p = 0.549), pre-term delivery (3.7% vs. 1.9%, p = 0.500), large for gestational age (5.5% vs. 5.5%, p = 1) or small for gestational age infants (11.1% vs. 9.3%, p = 1) in pre- vs. post-exposure pregnancies. Subgroup analysis demonstrated a lower gestational weight gain with metformin use during pregnancy but was not statistically significant (5.8 ± 9.1 kg vs. 8.2 ± 9.5 kg, p = 0.369). The proportion of women with inconsistent obesity medication use during the study period was higher in those who conceived compared to those who did not (100% vs. 36.5%).

Conclusion

Preconception liraglutide exposure, followed by discontinuation before pregnancy, was associated with weight regain but not with excess gestational weight gain in our within-individual design. Despite a small sample size, we did not observe increased adverse gestational outcomes in the post-exposure pregnancies.